Nanoparticle Clearance is Governed by Th1/Th2 Immunity and Strain Background by Jones, Stephen
 
 
 
 
NANOPARTICLE CLEARANCE IS GOVERNED BY TH1/TH2 IMMUNITY AND 
STRAIN BACKGROUND 
 
Stephen W. Jones 
 
 
A dissertation submitted to the faculty at the University of North Carolina at 
Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in the department of Cell Biology in the School of Medicine. 
 
 
 
Chapel Hill 
2013 
 
 
 
 
                                                                                   Approved by  
                                                                                 James Bear 
                                                                                     Keith Burridge  
                                                                                        Richard Chenny  
                                                                            Ian Davis  
      Mohanish Deshmukh  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013 
Stephen W. Jones 
ALL RIGHTS RESERVED 
 
iii 
 
 
 
ABSTRACT 
Stephen W. Jones: Nanoparticle Clearance is Governed by Th1/Th2 Immunity 
and Strain  
(Under the direction of James E. Bear) 
Extended circulation of nanoparticles in blood is essential for most clinical 
applications. Nanoparticles are rapidly cleared by cells of the mononuclear 
phagocyte system (MPS). Approaches such as grafting polyethylene glycol onto 
particles (PEGylation) extend circulation times; however, these particles are still 
cleared and the processes involved in this clearance remain poorly understood. 
Here we present a novel assay using intravital microscopy for the quantification 
of nanoparticle clearance, allowing us to determine the effect of mouse strain and 
immune system function on particle clearance. We demonstrate that mouse 
strains which are prone to Th1 immune responses clear nanoparticles at a slower 
rate than Th2-prone mice. Using depletion strategies, we show that both 
granulocytes and macrophages participate in the enhanced clearance observed 
in Th2-prone mice. Macrophages isolated from Th1 strains take up fewer 
particles in vitro than macrophages from Th2 strains. Treating macrophages from 
Th1 strains with cytokines to differentiate them into M2 macrophages increases 
the amount of particle uptake. Conversely, treating macrophages from Th2 
strains with cytokines to differentiate them into M1 macrophages decreases their 
particle uptake.  
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CHAPTER ONE: INTRODUCTION 
Nanoparticles in medicine 
Nanoparticles have been investigated for medicinal applications for over 
40 years (Chakraborty et al., 2013). Nanoparticle use in medicine can be broadly 
grouped into two categories, particles used for therapeutic applications in which 
the particle serves as therapeutic vehicle, and particles used for diagnostic 
applications. For the majority of nanoparticle therapeutics the principle is to 
immobilize a therapeutic agent within the matrix of a nanoparticle and thereby 
alter the pharmacokinetics (PK) of the therapeutic agent. The guiding principle 
behind this is that therapeutic agents that are normally toxic, unstable, or 
insoluble can be sequestered within the particle until they can be released at an 
appropriate time and place.  In most systems the particle utilizes a targeting 
agent such as an antibody or a DNA aptamer to direct the particle to a particular 
physiological destination (Beech et al., 2013; Fokong et al., 2012; Lammers et 
al., 2012; Li et al., 2013b; Shin et al., 2013). Once present in the desired location 
in the body the particle either degrades naturally or is triggered to degrade by 
altered physiological conditions such as low pH, reducing environment, or 
enzymatic activity. The degrading particle releases the encapsulated therapeutic 
agent upon degradation thereby targeting the majority of the agent to the site of 
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physiological interest and limiting off target effects (Morachis et al., 2012b). For 
diagnostic applications particles are functionalized with materials that can be 
detected with medical technology such as radiolabels for PET/SPECT imaging, 
MRI contrast agents, or fluorophores for fluorescent imaging (Feng et al., 2013; 
Gu et al., 2013; Wadajkar et al., 2013). Again in most circumstances diagnostic 
nanoparticles are conjugated with targeting agents to direct them to a site of 
interest in the body to aid physicians in the diagnosis and assessment of 
pathological conditions. Despite decades of work and thousands of papers 
published on the topic of nanomedicine, only two nanoformulations have been 
approved for clinical use in the USA. Abraxane which is a naoparticle formulation 
of albumin and paclitaxel, and doxil a liposomal formulation of doxorubicin 
(Coleman et al., 2006; Gradishar, 2006a; Krown et al., 2004). While there is still 
significant hope that nanoparticles will play a major future role in the clinic it has 
become clear that several major hurdles still must be overcome before 
nanotherapies will be widely efficacious. Here we will examine issues related to 
the response of the immune system to nanoparticles in blood. 
Classes of Nanoparticles 
A wide variety of materials schemes have been developed to generate 
nanoparticles for medical applications. Different particles with different material 
properties will show quite different capacities to bind drugs or therapeutic agents, 
utilize targeting strategies, show varying PK, and varying toxicology. Polymeric 
nanoparticles (Fig 1 A), are one of the most common types being researched for 
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medical applications. They can be made out of a very wide variety of materials 
with varying properties, can be easily designed to hold drugs inside the particle, 
can be functionalized with surface ligands of choice, and benefit from a huge 
amount of chemistry and materials knowledge of polymers and their properties. 
However it is challenging to make polymer particles smaller than 80-100nm, and 
they often show a wide range of sizes within one batch (Feng et al., 2013; 
Morachis et al., 2012a; Zhang et al., 2013). Polymeric micells (Fig 1 B) are 
formed by generating a polymer shell with one surface (typically the interior) 
being hydrophobic and the other being hydrophilic. The interior of the particle is 
typically filled with an oil droplet that can dissolve large amounts of hydrophobic 
drugs in the hydrophobic interior. The hydrophilic exterior can then be 
functionalized with stealthing or targeting ligands as needed. They can typically 
carry larger payloads of drug than polymer particles of the same size and can be 
made smaller, down to about 20nm. But they are often unstable in vivo and it is 
difficult to control the release of drugs from the interior of the particle (Fokong et 
al., 2012; Muthiah et al., 2013; Yurgel et al., 2013). Dendrimers (Fig 1 C) are 
large branched single chain polymers which contain within them many binding 
domains for therapeutics or imaging agents within them. The dendrimer is quite 
small for a nanoformulation often being less than 20nm in size. The highly 
hydrophilic nature of dendrimers give them excellent PK, but it is difficult to load 
large amounts of drug on a dendrimer and difficult to effectively target them (Liu 
et al., 2013; Ma et al., 2013; Ravina et al., 2010; Singha et al., 2011). Liposomes 
(Fig 1 D) are the most studied nanoformulation for medical applications and the 
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first nanodrug to get full approval in US for use (Doxil) (Biganzoli et al., 2007; 
Coleman et al., 2006). They are created by making a lipid bilayer typically 
~100nm in size that contain a water droplet on the inside that can be loaded with 
hydrophilic therapeutics.  The outer surface of the liposome can then be 
functionalized with targeting agents or stealthing ligands.  Liposomes are easy to 
make and very biologically compatible with low toxicology and good PK, but like 
polymeric micelles they are unstable and difficult to control drug release from 
(Chattopadhyay, 2013; Jolck et al., 2010; Naik et al., 2013; Qian et al., 2012). In 
recent years some labs have started referring to viruses as nanoparticles (Fig 1 
E), which is a technically correct definition. This has caused virus mediated 
genetic therapies to become incorporated into nanomedicine. In addition some 
effort has been made to formulate viral particles that contain a drug in the interior 
instead of genetic material. Viruses have the advantages of excellent natural 
targeting, cell penetrating, and controlled delivery of cargoes. However. viruses 
often illicit an immune response which limits their efficacy in vivo and can be 
dangerous to the patient. It is also difficult to produce large amounts of virus 
(Lentz et al., 2012; Manjila et al., 2013; Sun et al., 2013b; Usme-Ciro et al., 
2013). Finally carbon nanotubes (Fig 1 F), have shown some potential as 
diagnostic agents due to their unusual optical and magnetic properties that make 
them easy to detect in vivo. However it is difficult to get nanotubes to 
demonstrate good PK, and difficult to target them to sites of interest for 
diagnostics. There have also been several studies suggesting that nanotubes 
may not break down in vivo and can contribute long term to toxicological events 
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(Li et al., 2013a; Reynolds et al., 2013; Sun et al., 2013a; Tan et al., 2011; 
Yildirimer et al., 2011). 
 
The PRINT® System for Nanoparticle Synthesis. 
Recently a new technique known as particle replication in non-wetting 
templates (PRINT) has been developed for the generation of hydrogel 
nanoparticles  with a high level of control over the size and shape of the particles 
(Rolland et al., 2005). This allows for more precise experiments comparing 
effects of size and shape on particle PK (Gratton et al., 2007), cell entry (Gratton 
et al., 2008a; Gratton et al., 2008c), targeting (Wang et al., 2010), PEG stealthing 
(Perry et al., 2012) and novel classes of microparticles (Merkel et al., 2011).  In 
all cases by taking advantage of the nature of the PRINT system particles with 
limited diversity of size and shape can be compared much more rigorously than 
more heterogeneous particle populations, which allows for more detailed 
experiments with better controls. 
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The MPS system 
The arm of the immune system that is most commonly associated with 
nanoparticles is the reticuloendothelial system (RES)/mononuclear phagocyte 
system (MPS). The MPS system broadly consists of tissue macrophages and 
dendritic cells (DCs) found in the spleen, liver, and lungs as well as monocytes in 
the spleen and blood (Miyata and van Eeden, 2011; Moghimi et al., 2012; Wynn 
et al., 2013). In addition some authors have recently suggested that neutrophils 
in the blood should also be considered part of the MPS due to their similar 
function and behavior to other MPS cells, thoughtraditionally neutrophils have not 
been considered a part of the MPS system. The MPS system has been well 
characterized as functioning as the innate immune system’s effecter arm in the 
blood (Fitrolaki et al., 2013; Kono et al., 2012; Ogiku et al., 2011). Additionally in 
pathological contexts the MPS system, especially the DCs, function as the main 
antigen presenting cells in the spleen for activation of adaptive T and B cell 
responses. This particular function will not be considered further here, but has 
been extensively reviewed recently (Blum et al., 2013; Fehres et al., 2013; Guery 
and Hugues, 2013). 
  In the liver kuppfer cells, tissue macrophages play a critical role under 
normal physiological conditions to remove microbes and microbial products from 
blood that enters the liver from the intestines (Crispe, 2009; Traeger et al., 2010). 
To facilitate this process, the kuppfer cells are found in the small liver sinusoids 
where blood flow is slow and the kuppfer cells project large numbers of filopodia 
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into the lumen of the blood vessel. When phagocytic receptors on the filopodia 
engage microbial surfaces the microbes are bound and rapidly internalized by 
the kuppfer cell, this process prevents bacteria and other microbes that 
commonly enter the blood in the intestines from passing into the rest of the body 
and causing sepsis (Gregory et al., 2002; Gregory and Wing, 2002; Shih-Ching 
et al., 2004; Wong et al., 2010). Kuppfer cells have also been implicated in a 
wide range of pathological conditions including liver fibrosis (Frasinariu et al., 
2013; Purohit and Brenner, 2006; Tomita et al., 2013), fatty liver disease (Koek et 
al., 2011; Sawada et al., 2013), hepatic cancer (Bortolami et al., 2002; Van den 
Eynden et al., 2013), malaria (Frevert et al., 2008; Tavares et al., 2013a; Tavares 
et al., 2013b), and alcoholic liver disease(Bala et al., 2012; Petrasek et al., 2012; 
Szabo et al., 2012; Wan et al., 2013). If microbes are introduced directly into the 
blood, it is well known that the majority of microbes will be cleared by the action 
of kuppfer cells in the liver (Shou et al., 1994). In the case of genetic or 
pharmacolgical treatments which significantly blunt the activity of kuppfer cells 
there is a significantly increased risk of death during sepsis (Knoferl et al., 2002). 
After the liver the second largest collection of MPS cells that access the 
blood is found in the spleen, where at least eight different distinct populations of 
macrophages can be found (den Haan and Kraal, 2012). The exact role and 
nature of all of the subpopulations of splenic macrophages is poorly understood, 
but most of the minor populations are believed to be important in antigen 
presentation (Randolph et al., 2008; Tacke et al., 2007). The most abundant type 
is the well-studied red pulp macrophage. Red pulp macrophages, as their name 
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implies, are located in the red pulp of the spleen. Under normal physiological 
conditions they remove aged red blood cells from blood as it passes through the 
spleen (Ganz, 2012). This action plays an important role in preventing anemia 
and inflammation from the lysis of aged red blood cells in inappropriate locations 
in the body (Kovtunovych et al., 2010). In the case of sepsis red pulp 
macrophages will bind and phagocytose microbes in the blood as it passes 
through the spleen. In the case of a normally functioning immune system the 
spleen will clear the second largest amount of microbes during sepsis after the 
liver, with the red pulp macrophage being the dominant player in this process. 
The activity of macrophages in the lung is highly inconsistent from one species to 
another. All mammals contain large numbers of macrophages in the lungs, 
however in some species such as rodents (Fels and Cohn, 1986) the 
macrophages are polarized into the airways and do not respond to the presence 
of microbes in the blood of the lungs and therefore clear only small numbers of 
microbes during sepsis (Fels and Cohn, 1986). However in some larger 
mammals such as dogs, macrophages in the lungs appear to respond both to 
microbes in the airways and the blood allowing them to clear microbes in the 
case of sepsis (Merrill, 1990). Human lung macrophages appear to respond both 
to pathogens in blood and in the airways making the lung the third most prevalent 
site of clearance in humans after liver and spleen (Merrill, 1990). 
Monocytes exist in the body in two distinct populations, CX3CR1 high and 
low. CX3CR1 high monocytes are found in the blood and peripheral blood 
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vessels under normal conditions where they appear to perform a patrolling 
surveillance function. In the case of injury CX3CR1 high monocytes quickly 
migrate into the site of injury where they first release cytokines and chemokines 
to draw other immune cells to the site of injury, then differentiate into tissue 
macrophages to assist in the clearance of invading microbes/cellular debris 
(Auffray et al., 2007; Geissmann et al., 2010). CX3CR1 low monocytes are 
normally resident in the spleen, but upon injury the chemokines during injury 
induces CX3CR1 monocytes to migrate from the spleen into the blood. After 
circulation in the blood they then enter the site of injury where they differentiate 
into macrophages (Swirski et al., 2009). 
Neutrophils are the most prevalent immune cell in the body. They are 
generated at a constant high rate in the bone marrow, circulate in the blood for 
18hrs-3 days, after which time they apoptose and are removed from the blood by 
macrophages in the spleen, liver and bone marrow (Maugeri et al., 2009). In the 
case of injury and/or infection neutrophils quickly enter the site of injury where 
they can act as phagocytes to remove pathogens, or in other circumstances 
release their granular contents of anti-microbial enzymes and reactive oxygen 
species in an attempt to kill invading pathogens (Pittman and Kubes, 2013). 
Other studies have shown neutrophils are important in the phagocytic clearance 
of activated platelets in blood, where they bind to and internalize platelets, and 
then transit to the liver, spleen or bone marrow to be phagocytically cleared by 
macrophages (Manfredi et al., 2010; Maugeri et al., 2012). Although neutrophils 
have long been known to be phagocytic they are often not grouped as part of the 
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MPS system likely due to their different life cycle and microbial killing activities. 
However, recently some authors have suggested that due to their lineage, 
motility and phagocytic capacity they should more properly be classified as an 
MPS cell (Rabinovitch, 1995; Silva and Correia-Neves, 2012). Surprisingly 
despite they abundance and phagocytic capacity few nanoparticle studies have 
examined their role in particle clearance. It has been shown however that certain 
particle types can be found in neutrophils after intravenous injection (Leuschner 
et al., 2011). In addition it has been shown that in vitro nanoparticles can be 
phagocytosed by neutrophils and induce neutrophil netting, a process in which 
the nuclear contents of the neutrophils are mixed with the granular contents and 
then exocytosed to create a DNA, granular, extracellular, anti-microbial net 
(Bartneck et al., 2010). 
MPS clearance of nanoparticles 
Early studies of the PK of nanoparticles injected intravenously showed 
surprisingly fast clearance of particles from the blood (Fernandez-Urrusuno et al., 
1996). Upon further examination of the biodistribution (BD) of the particles it was 
shown that the majority of the particles were located within the kuppfer cells of 
the liver and the red pulp cells of the spleen (Illum and Davis, 1984; Illum et al., 
1984). This result has subsequently been repeated with a wide variety of 
nanoforumlations with widely divergent physical and chemical characteristics 
(Zamboni et al., 2012). A large amount of research has been done examining the 
interactions between macrophages and nanoparticles in vitro to attempt to 
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indentify key factors involved in particle binding and clearance by macrophages. 
No study to date has been able to truly prevent all binding and clearance of 
particles, but several physical and chemical characteristics such as 
hydrophobicity, strong charge, rigidity, size, and the rate at which serum proteins 
bind to a particle have been identified as playing a negative role (Moselhy et al., 
2000). From this work a general consensus has emerged that particles less than 
500nm, that are flexible, hydrophilic and uncharged will demonstrate the best PK 
in vivo. Other studies have attempted to determine which specific receptors on 
macrophages bind to particles to mediate clearance. These studies have been 
primarily in vitro using immortalized cell lines, and often non-specific inhibitors 
with many characterized off target effects. These caveats make drawing any 
strong conclusions about important receptors difficult, but they do provide an 
initial list of suspects including scavenger receptor A (Patel et al., 2010), Fc 
gamma receptor three (Yang et al., 2010), compliment receptor 3 (Sahay et al., 
2010), among others. 
 The most commonly used strategy to extend the circulation time of nanoparticles 
in vivo has been to graft a thick coating of high molecular weight polyethylene 
glycol (PEG) to the surface of particles. PEGylation works by providing a 
hydrophilic low charge surface that coordinates a shell of water molecules 
around the surface of the particle which slows the rate of protein adsorption to 
the particle (Owens and Peppas, 2006; Zamboni et al., 2012). PEG coating has 
been shown to significantly increase the circulation times and alter the BD of 
nanoparticles in vivo (Papahadjopoulos et al., 1991). However PEG does not 
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completely prevent clearance of particles by MPS cells, instead it slows the 
kinetics. In addition there are reasons to believe that PEG is a less than ideal 
solution for clinical applications. First it appears that PEGylation typically 
competes with targeting strategies as targeting molecules must protrude past the 
PEG layer and be present in sufficient quantities to result in targeting. This has a 
tendency to disrupt the coordinated shell of water around the particle, and 
creates the possibility of MPS cells binding directly to the targeting ligand, 
resulting in clearance (Pardeshi et al., 2012), or for serum proteins to bind to the 
particle opsinizing it. It has also been shown that a large number of patients 
treated with PEGylated agents will develop short term anti-PEG IgM antibodies 
(Ishihara et al., 2009; Shimizu et al., 2012), this response is transient, typically 
lasting for only a few weeks, but it significantly limits the flexibility of dosing 
schedules for PEGylated agents. In addition recent work has shown that as much 
as 25% of the population has circulating anti PEG IgG antibodies due to the 
presence of PEG in a large number of consumer products (Garay et al., 2012). 
While the combination of these factors suggests that PEG is not a sufficient 
solution for MPS clearance of nanoparticles, surprisingly little work has been 
done studying the biology of clearance, or coming up with alterative solutions to 
PEG for extending the circulation of nanoparticles.  
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Nanoparticle PK assays 
The study of nanoparticle PK has typically utilized a blood draw assay in 
which nanoparticles are injected into a large number of animals at time zero. At 
various time points after injection the animals are sacrificed and bled. The 
collected blood can then be assayed for concentrations of nanoparticles by using 
reporters such as fluorescence or radiation (Zamboni et al., 2012). In the case of 
inorganic nanoparticles the concentration can be directly assayed by detecting 
the presence of elements in the particles not found in biological samples such as 
gold, in the case of gold nanoparticles or cadmium and selenium in the case of 
quantum dots (Dreaden et al., 2012a; Dreaden et al., 2012b). These assays are 
advantageous as they are simple to perform; the data can be applied to existing 
pharmacokinetic models for small molecule PK, and can provide direct 
concentrations of nanoparticles in blood and/or tissue. There are however 
several disadvantages to these assays: First this technique requires the use of 
large numbers of animals and therefore large amounts of nanoparticles, as a 
group of animals is required at every time point. Second these assays offer 
limited temporal resolution, it is difficult to get data points for less than 1-2min 
after injection of particles making the baseline value unclear, and every time 
point assayed requires the use of additional animals and particles. Third it is 
common for these types of experiments to result in high errors as it is difficult to 
sacrifice animals and bleed them in a controlled, repeatable way. These 
limitations make this type of assay unappealing for use when attempting to 
screen formulations of nanoparticles or animal models of disease due to the fact 
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that large numbers of often difficult to manufacture experimental particles or 
expensive/rare animals must be used. An alternate assay that allows for PK data 
from a small number of animals usingfewer particles and higher temporal 
resolution is critically needed by the field to allow for rapid screening of particles 
and animal models. 
Intravital microscopy 
Intravital microscopy is an emerging technique in biological sciences that 
allows for the direct imaging of cells, molecules, tissues, etc. in living animals. It 
is highly advantageous over traditional in vitro tissue culture based imaging for 
the obvious reason of being performed in a physiologically relevant system. 
Intravital microscopy is most commonly performed using a multiphoton 
microscope (Niesner and Hauser, 2011). This type of scope uses two carefully 
aligned infrared laser lines that cross at a precisely defined position. At the point 
where the two lasers cross their energy is roughly doubled allowing them to 
excite photophores that typically are excited by visible light (Benninger et al., 
2008). This is advantageous as infrared light exhibits far greater tissue 
penetration than visible light allowing for the stimulation of photophores that 
would otherwise be too deep in tissue to be imaged (Bakalova, 2007). However, 
for imaging in tissues that are shallower such as the epidermis, it is often 
advantageous to use traditional laser scanning confocal microscopy as tissue 
penetration is less important and greater resolution can be achieved with 
traditional confocal microscopy. Intravital microscopy has been used recently to 
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study diverse biological processes including cancer invasion (Uchugonova et al., 
2013), development (Canaria and Lansford, 2010), immune function (Sumen et 
al., 2004), neurobiology (Garaschuk et al., 2006), as well as many others. In 
nanomedicine intravital microscopy is slowly gaining traction and has recently 
been used to assay the effect of size and shape on tumor extravasation of 
particles (Smith et al., 2012), targeting of particles to neovasculature (Smith et 
al., 2008), the circulation of gold nanoparticles (Tong et al., 2009b), and the 
uptake of particles by tumors (Smith et al., 2010). By combining the knowledge 
and resources for intravital imaging of the immune system with intravital imaging 
of nanoparticles, we may be able to better understand the clearance of 
nanoparticles by the immune system. In addition, by directly imaging particle 
circulation in blood it is possible to use intravital microscopy as an alternative 
method for assaying nanoparticle circulation times that avoids many of the 
traditional complication of nanoparticle PK assays. 
Th1/Th2 immunology 
In recent years, the systems regulating the immune system and immune 
function have begun to be elucidated. At this point, the central cell controlling the 
immune network is known to be the CD4 positive (CD4+) T cell. These cells are 
the cornerstone of the adaptive immune system and serve as one of the major 
connection points between the innate and adaptive immune system (Schmitt and 
Williams, 2013). CD4+ T cells have no direct effector function on pathogens . 
However, upon stimulation with antigen and other co-stimulatory molecules 
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CD4+ T cells take on one of at least four different classes: the T helper cell, the 
Th1 T cell, the Th2 T cell, and the Th17 T cell (Boswell et al., 2011; Muranski and 
Restifo, 2013; Stadecker et al., 2004; Tundup et al., 2012). These populations 
are defined by the types of cytokines and chemokines that they secrete, and 
thereby inform other immune cell behavior. T helper cells are considered to be 
tolerogenic; they react to autoantigens and suppress the activity of CD8 killer T 
cells, and B cells that recognize the self antigen (Schmitt and Williams, 2013). 
They are characterized to secrete the cytokines interleukin 9 (IL-9), interleukin 10 
(IL-10), and tissue growth factor beta (TGF-beta). Th1 T cells are typically 
elucidated by bacterial infections, they release interferon gamma (IFNg) as their 
primary effecter molecule (Cope et al., 2011). IFNg functions primarily to prime 
and activate cells of the innate immune system to fight microbial pathogens, by 
upregulating molecules required for the killing of bacteria and yeast. In addition, 
Th1 T cells contribute to inflammatory conditions in infected tissue, which allow 
for the entry of immune cells, the slowing of bacterial growth, and the influx of 
plasma carrying immune molecules such as antibodies and complement 
(Paulnock, 1992; Wynn et al., 1992). Macrophages activated by Th1 T cells are 
termed M1 or classically activated macrophages (Novak and Koh, 2013). Th2 
cells are classically thought of to be induced by parasitic infections (Pearce and 
Reiner, 1995). They release TGF-beta, IL-4, IL-7 and IL-13 as effector 
molecules. These molecules stimulate the division and activation of cells involved 
in the elimination of parasites such as eosinophils and basophils, as well as 
promote a robust antibody response from B cells (Pulendran and Artis, 2012). 
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Macrophages activated by Th2 T cells are termed M2 macrophages (Mantovani 
et al., 2002). Th17 T cells are most classically thought of as being elucidated by 
viral infections (Romagnani, 2008), and have also been shown to mediate many 
autoimmune diseases (Brembilla and Chizzolini, 2012). IL-17 is the primary 
cytokine of Th17 cells. IL-17 strongly induces the actively of CD8 killer T cells to 
fight viral pathogens.  
It is known that in humans exposure to certain types of infections early in 
life will have a tendency to polarize the immune system more towards one of 
these types of CD4+ T cell programs. This polarization will, in turn, cause an 
individual to be better protected from some types of pathologies and be more 
vulnerable to others (Grogan and Locksley, 2002). Despite the fact that these 
types of immune priming events are critical for immune function, nothing is 
currently known as to how CD4+ T cell priming affects the clearance of 
nanoparticles by the immune system. Fortunately, this is a tractable problem due 
to the fact that several laboratory mouse strains are known to naturally polarize 
towards one type of immune response or another. For instance, the strain 
C57BL/6 has been shown to always have a Th1 type immune response, while 
the strain BALB/c always has a Th2 type response (Mills et al., 2000). 
M1/M2 Macrophages 
In recent years, studies of macrophages have determined that based on 
the cytokine environment present, macrophages can polarize into at least two 
distinct phenotypes (Mills et al., 2000). The cytokines produced by Th1 CD4+ T 
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cells, primarily IFNg have long be known to induce a state of macrophage 
activation that is now known as classical or M1 activation (Nakano et al., 2001). 
In this case, macrophages are prepared for defense of tissue from invading 
microbes such as bacteria and fungi. To accomplish this, macrophages alter their 
morphology to become mesenchymal and upregulate enzymes involved in the 
formation of reactive oxygen species (ROS) such as nitric oxide synthase (iNOS) 
and microbial killing enzymes such as granzyme (Mills et al., 2000). Studies have 
shown that M1 polarized macrophages are more successful at both 
phagocytosing bacteria, and killing both phagocytosed bacteria and bacteria in 
surrounding tissue. M1 macrophages also secrete pro-inflammatory cytokines 
and chemokines to draw other immune cells to site of infection and activate them 
(Martinez et al., 2006). These effects render M1 macrophages highly effective at 
the elimination of invading microbes, but are also highly destructive to the 
surrounding tissue due to the high levels of inflammation they induce and direct 
damage from ROS (Nishio et al., 2005). More recently, it has been discovered 
that cytokines produced by Th2 immune responses also elucidate an activated 
state in macrophages, but with very different characteristics; these are known as 
alternatively activated or M2 macrophages (Mantovani et al., 2002; Tugal et al., 
2013). M2 macrophages are thought to be involved primarily in the resolution of 
inflammation and tissue/wound repair (Mills et al., 2000). M2 macrophages 
maintain the standard macrophage amoeboid morphology allowing them to be 
more motile in tissue. They downregulate ROS producing enzymes such as 
iNOS and instead upregulate arginase, thereby preventing metabolism of 
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arginine to NO. In addition, a wide range of scavenger and lectin receptors are 
upregulated likely to help with the removal of microbial and cellular debris (Noel 
et al., 2004). Likely due to the upregulation of these receptors, M2 macrophages 
have been shown to more readily phagocytose oxidized low density lipoproteins, 
apoptotic bodies, and latex beads (Chinetti-Gbaguidi et al., 2011; Durafourt et al., 
2012). Finally, M2 macrophages have been shown to secrete anti-inflammatory 
cytokines and induce division of tissue cells for the repair of injury (Cudejko et al., 
2011).  
The current model of infection suggests that macrophage function is a 
two-step process. Initially, macrophages present at the site of infection or 
monocytes recruited to the site of infection differentiate and/or polarize into M1 
macrophages to fight microbes present at the infection. However, as runaway 
inflammation is highly damaging to the tissue after a certain length of time, M1 
macrophages either repolarize to or are replaced by M2 macrophages. The M2 
macrophages then function to remove cellular and microbial debris and to 
promote tissue growth and repair (Biswas et al., 2012). 
Despite the marked difference in macrophage behavior between M1 and 
M2 macrophages and the fact that macrophages are a key player in the 
clearance of nanoparticles in vivo, no one has examined the effect of M1 vs. M2 
polarization on nanoparticle clearance. 
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CHAPTER TWO: AN INTRAVITAL MICROSCOPY ASSAY FOR ASSESING 
THE RELATIVE PHARMACOKINETICS OF NANOPARTICLES IN VIVO 
As discussed in chapter 1, the majority of PK assays for nanoparticles rely 
on a system of blood draws from multiple mice at certain defined timepoints to 
generate concentration of particles in blood over time. These assays are limited 
in their temporal resolution, error measurements, and repeatability due to the 
large number of mice required. For instance, using a fairly minimal number of 
time points for PK (control, 5min, 15min, 30min, 1hr, 2hr, 6hr, 12hr, 24hr) and a 
minimal number of mice (3 per time point), a blood draw PK experiment requires 
27 mice for completion. Using a low dose of particles (15mg/kg) in an average 
weight young female mouse (20g) ends up requiring ~8mg of particles to be 
synthesized. For a better dataset that is more likely to reveal significant 
differences in particle PK, mouse and particle numbers will need to increase by 
at least 50%. This high requirement for numbers of mice and particles becomes 
extremely demanding on resources and time, especially when using difficult-to-
synthesize experimental particles and/or difficult to maintain mouse models. 
Therefore, traditional blood draw PK assays are an unappealing method for 
screening various formulations of nanoparticles and/or mouse models of 
diseases or genetic manipulations. A better-functioning assay would involve the 
use of fewer mice (ideally less than 10), and therefore fewer particles, have high 
temporal resolution and low error, and be able to be completed in a short time 
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frame. This chapter will be devoted to describing the development of a novel 
intravital microscopy assay for nanoparticle circulation times in vivo that 
addresses the above needs. A description of this assay has been published in 
PNAS by Merkel et. al. (REF). 
Detailed protocol: These assays were performed using an Olympus IV100 
laser scanning intravital microscope. However, in principle this assay could be 
performed with limited modifications with any fluorescence microscope capable 
of supporting a heating pad during imaging. 
Mouse preparation: Experiments were performed on young healthy female 
BALB/c mice with an average weight of 20g. Mice were prepared by 
anesthetization with inhalable isoflurane gas at 2% in O2. Once mice were fully 
anesthetized, a pediatrics 27 gauge catheter was inserted into the tail vein and 
immobilized with superglue. The ear of the mouse was prepared by application of 
men’s Nair to the ear for 1min, followed by washing the ear 4X with room temp 
water to remove all Nair and clean the ear. The mouse’s ear was than observed 
for ~2min for any signs of irritation or inflammation from the Nair such as 
excessive redness especially around the blood vessels, swelling, or peeling of 
skin. If any of these were observed, the mouse was returned to the cage for 
future use. If no inflammation was observed, the mouse was carefully moved to 
the stage of the IV100 scope with care taken to not disturb the catheter. On the 
stage of the scope, the mouse’s face was placed in a nose cone which delivered 
2% isoflurane gas continuously. The heating pad on the stage was set to 37C 
and the ear was immobilized using two-sided tape on an aluminum block by 
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placing the outer edge of the ear on the tape, and then gently rolling a finger over 
the ear from the outer edge towards the head to flatten the ear. It is important to 
spread the ear from the outer edge in as going the other direction can result in 
burst capillaries at the outer edge of the ear and inflammation. If at any point in 
the process inflammation is observed in the ear, the experiment should be 
stopped as inflammation results in particles accumulating in the site of the 
inflammation and, therefore. gives false PK data. 
Imaging setup: Blood vessels were located in the mouse’s ear by 
illuminating the ear with white light and then imaging with the green fluorescence 
channel (excitation 488nm, short pass filter 506-540nm). The 506-540nm 
component of the white light was reflected off of tissue in the mouse ear to 
produce a bright signal, while the hemoglobin in the blood vessels absorbs light 
in those wavelengths resulting in dark regions where blood vessels are located 
(Figure 1 A). 
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In initial experiments the location of vessels was confirmed by injection of 
vascular contrast agents such as BSA conjugated to Alexa647 dyes (Figure 1 B). 
After blood vessels were located, the scope was set to image under the same 
protocol that would be used for particles (example, 1 frame/sec, 70% 633 laser, 
PMT gain 700, offset 0, dwell time 10µs/pixel, 320X320 pixels) for 15 min. After 
15 min the movie was examined for evidence of significant drift in the XY or Z 
dimensions. If drift was observed the ear would be removed from the block, and 
a fresh piece of tape placed on the block followed by retaping the ear and 
another 15min imaging. When the ear was shown to be stable we proceeded to 
the particle imaging. 
Particle imaging: For initial experiments developing this intravital 
microscopy assay we used PRINT® microparticles, utilizing the PRINT system 
as described (ref). Imaging sessions lasted 2hrs with frames being acquired 
every 5sec throughout. Before injecting particles blood vessels were located with 
atofluorescence or fluorescent BSA (Fig 2 A). Four frames were acquired 
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prior to particle injection in the far red channel to serve as a baseline reading for 
particle intensity. 500µg of particles were then injected followed by flushing the 
catheter with 40µl of heparin lock solution. The particles quickly filled the blood 
vessel and were visualized by the scope (Fig 2 B and C). Throughout the course 
of the imaging the number of circulating particles decreased as expected (Fig 2 
D). To examine if the assay showed differences in circulation times for 
microparticles of different stiffness, as would be expected, we dosed mice with 
four different particle types with Young’s modulus’s ranging from 63.9kPa to 
7.8kPa.  
Image analysis: Movies were exported as TIF files to ImageJ for analysis. 
In ImageJ individual TIFs were complied together into stacks. Each stack was 
condensed by averaging four frames together using the intensity projection 
plugin. This resulted in 360 frames over 2hrs, or one frame for every 20sec. A 
straight line region of interest (ROI) was drawn in the main vein present in each 
movie. The average fluorescent intensity in the ROI was calculated for each 
frame of the movie. This data was exported to Microsoft Excel or GraphPad 
Prism for further analysis. Analysis included calculating lines and area under the 
curve to compare circulation times between particles of different modulus, or 
deriving PK values such as particle T1 and T2 half-lives and elimination volumes 
(Table 1). Analysis revealed that as expected decrees in particle modulus 
resulted in increases in particle circulation times. 
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TABLE 1. 
Modulus values and compartmental analysis of RBCM particles from intravital 
microscopy experiments 
% Cross-
linker 
Modulus of 
bulk material, 
kPa 
Distribution 
half-life, h 
Elimination 
half-life, h 
AUC, 
fluoresence* h 
Average 
R2 
10% 63.9 ± 15.7 0.038 ± 0.0012 2.88 ± 0.92 0.65 ± 0.14 0.8966 
5% 39.6 ± 10.4 0.066 ± 0.036 5.12 ± 2.17 0.76 ± 0.57 0.9029 
2% 16.9 ± 1.7 0.15 ± 0.025 7.12 ± 0.82 1.35 ± 0.26 0.9468 
1% 7.8 ± 1.0 0.35 ± 0.13 93.29 ± 31.09 15.44 ± 15.63 0.9330 
*Ranges given represent one standard deviation. Values were derived from 
scans of three mice. 
 
Confirmation of intravital results: To confirm that the new intravital PK 
assay was delivering valid results, we re-tested the results from with the 1% 
crosslinker using a traditional blood draw PK. A large number of mice were 
injected with 500µg particles at the beginning of the experiment. Four mice were 
sacrificed at 5min, 30min, 1hr, 2hrs, 12hrs, 24hrs, 48hr, 138hrs post injection. 
Mice were sacrificed by cardiac puncture and the blood and organs were 
collected. The fluorescence intensity in the blood was calculated for each time 
point and the PK values for the micro particles were derived from these 
measurements (Table 2). No statistical difference was observed between the 
data set from the intravital PK and traditional blood draw PK experiments.   
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TABLE 2. 
Pharmacokinetic parameters for 1% cross-linked RBCMs calculated from blood 
draws taken out to 5 d postinjection 
A, 
mg/mL 
B, 
mg/mL 
α, h-1 β, h-1 αt1/2, 
h 
βt1/2, h VC, 
mL 
AUC, 
mg  h/mL 
CLT, 
mL/h 
Vdβ, 
mL 
0.190 0.0482 0.241 0.00768 2.876 90.235 2.934 7.067 0.0990 12.894 
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CHAPTER THREE: THE EFFECT OF TH1 AND TH2 IMMUNITY AND 
MOUSE STRAIN ON NANOPARTICLE CLEARANCE 
INTRODUCTION: 
The potential clinical applications of nanoparticles and nanoformulations 
have been investigated for more than 30 years. Nanoparticle approaches have 
the potential to revolutionize drug delivery by allowing for the encapsulation of 
drugs with poor solubility or stability in a stable carrier particle. In addition, 
targeting nanoparticles to specific pathological sites may allow increased 
effective dose of drug at the needed site while decreasing systemic drug 
exposure, and therefore side effects. However, to date, only two 
nanoformulations for cancer treatment have been approved for clinical use (Doxil 
and Abraxane) (Coleman et al., 2006; Gradishar, 2006b; Krown et al., 2004). 
One major obstacle for the use of nanoparticles in vivo is rapid clearance by the 
cells of the reticuloendothelial system (RES)/ mononuclear phagocyte system 
(MPS) (Alexis et al., 2008; Leuschner et al., 2011; Nel et al., 2009; Zamboni et 
al., 2012). In addition to rapid clearance, variable activity of the MPS between 
patients leads to widely variable pharmacokinetics of nanoformulations in the 
clinic, reducing the efficacy of both approved and future experimental 
nanoformulations (Zamboni et al., 2009). The main strategy for extending the 
circulation time of nanoparticles is grafting of uncharged hydrophilic polymers 
onto the surface of particles for “stealthing”, with the most common polymer used 
being polyethylene glycol (PEG) (Owens and Peppas, 2006). PEGylation of 
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particles clearly extends their circulation time in vivo (Papahadjopoulos et al., 
1991; Zamboni et al., 2012); however, up to 25% of patients exhibit circulating 
anti-PEG antibodies prior to treatment, or develop anti-PEG antibodies after the 
first administration of PEGylated particles (Garay et al., 2012; Shimizu et al., 
2012). These factors limit the utility of PEGylation of nanoparticles in the clinic 
and suggest that a better understanding of the biomolecular interactions of 
nanoparticles and the MPS is critical for the development of alternative methods 
to PEGylation for the extension of nanoparticle circulation times in vivo.  
 
The MPS is comprised of the macrophages and dendritic cells located in 
the liver and spleen, as well as monocytes and other phagocytic cells in the 
blood and spleen. When nanoparticles are injected intravenously and begin to 
circulate in the blood, they make direct contact with these MPS cells. Once a 
particle is in contact with MPS cells, receptors on the cell surface either directly 
recognize the particle, or recognize opsonizing serum proteins that have become 
attached to the particle. This leads to internalization of the particle and 
sequestration in the MPS cells (Yoo et al., 2010). Extensive work has been done 
to understand particle uptake at the cellular level, with various studies implicating 
scavenger receptors (Patel et al., 2010), complement (Yang et al., 2010), and Fc 
receptors (Sahay et al., 2010). The majority of these studies have been 
conducted with immortalized macrophage cell lines in vitro, and with various 
types and sizes of particles. However, the physiological relevance of particle 
uptake by immortalized cell lines in vitro for clearance in vivo is unclear. 
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Another relevant factor that has received little attention in the nanoparticle 
field is the effect that global immune status, such as the balance of Th1/Th2 
cytokines and M1/M2 macrophages, has on the clearance process. During 
immune responses, helper T cells adopt distinct Th1 or Th2 identities, leading to 
the secretion of specific combinations of cytokines and chemokines that instruct 
a wide variety of immune cells, including macrophages [as reviewed in Murphy 
et. al. (Murphy and Reiner, 2002)]. The presence of Th1 cytokines has a 
tendency to polarize macrophages towards a pro-inflammatory M1 phenotype 
(Mills et al., 2000). Conversely, Th2 immune responses can induce macrophage 
polarization towards an anti-inflammatory M2 phenotype that promotes wound 
healing and the resolution of inflammation, yet is known to contribute to diseases 
such as allergies and asthma (Gordon and Martinez, 2010; Mills et al., 2000). In 
addition, M1 and M2 macrophages express different repertoires of phagocytic 
receptors, and may show differential efficiency of endocytosis and phagocytosis 
(Gordon and Martinez, 2010; Mills et al., 2000). It appears the effect of 
macrophage polarization on phagocytosis is target-dependent: M1 macrophages 
show enhanced phagocytosis of S. aureus (Krysko et al., 2011), while M2 
macrophages are more phagocytic towards myelin (Durafourt et al., 2012), 
apoptotic cells, and latex beads (Chinetti-Gbaguidi et al., 2011). Development of 
T cell based immune responses requires days to weeks, and would not be 
immediately provoked by exposure to particles. However, it is possible that 
Th1/Th2 priming from previous immune responses or differences in genetic 
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background could affect clearance of nanoparticles via changes in the relative 
number of M1 vs. M2 macrophages (Murphy and Reiner, 2002).  
 
Current techniques for assaying quantitative or relative nanoparticle 
pharmacokinetics (PK) have significant drawbacks for screening multiple particle 
types and/or animal models due to issues with time, expense, sensitivity, and 
temporal resolution (see Discussion). Intravital microscopy (IVM) is an appealing 
alternative for assaying relative PK of nanoparticles in vivo. IVM has been used 
to assay the accumulation of targeted particles in tumors (Smith et al., 2008), 
tissue (Hak et al., 2010), the circulation time of gold nanorods (Tong et al., 
2009a), the accumulation of particles in the liver (Cheng et al., 2012), the effect 
of size and shape on tumor extravasation (Smith et al., 2012) and the circulation 
of hydrogel microparticles (Merkel et al., 2011). In order to determine the roles of 
particle parameters and global immune status on nanoparticle PK, a calibration 
quality nanoparticle that has low batch-to-batch variability, with very low 
polydispersity is required. To this end, we used the Particle Replication in Non 
Wetting Templates (PRINT®) technique to generate particles of varying sizes. 
PRINT provides superior control over particle geometry and physical properties 
by taking advantage of a novel soft lithography technique for particle fabrication. 
This results in low batch-to-batch variability while having very low polydispersity 
values (Rolland et al., 2005) (Gratton et al., 2008b). Recent work has 
demonstrated that the PK of PRINT nanoparticles can be carefully and 
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reproducibly calibrated by adjusting the density of PEG chains present on the 
surface (Perry et al., 2012). 
 
In this study, we observed striking differences in nanoparticle clearance 
kinetics between commonly used ‘wild-type’ mouse strains using intravital 
microscopy and flow cytometry. We have identified the cell types and anatomical 
locations of this differential clearance and identified the global (Th1 vs. Th2) 
immune status as a critical factor in nanoparticle clearance in vivo.  
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RESULTS:  
Intravital microscopy (IVM) allows for rapid screening of nanoparticle 
clearance. 
The ability to easily and inexpensively screen different formulations of 
nanoparticles in animal models is an unmet need in the field of nanomedicine. To 
address this need, we have modified an intravital microscopy technique that we 
recently developed to measure the pharmacokinetics of red blood cell mimetic 
microparticles (RBCM) (Merkel et al., 2011). This technique allows for screening 
the relative nanoparticle resident times in the blood using as few as four animals 
per condition. In order to reduce variation in nanoparticles for these experiments, 
we have employed the PRINT technique to generate monodisperse 300 nm 
cylindrical PEG hydrogel nanoparticles containing far-red fluorescent dyes for in 
vivo and in vitro imaging (Fig. 5); these particles are similar in size and 
composition to those used in a recent study by our group (Perry et al., 2012). 
When injected intravenously (IV), these particles produce bright fluorescence in 
the vasculature of a mouse and can be easily imaged in the ear (Fig. 5A-C). A 
time vs. fluorescence intensity profile can then be generated, and the area under 
the curve (AUC) can be calculated (Fig. 5D). By comparing the AUC from 
different mice we can determine the relative exposure of nanoparticles to blood in 
vivo.  
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Figure 4: Characterization of particles used in experiments.  
(A) Size, PDI, and Zeta potential for all particles used. Size was determined 
by dynamic light scattering for 200nm PRINT particles and Qdots, 
fluorescence microscopy was used to determine size of microparticles. 
(B) Scanning electron micrograph of 200nm PRINT particles. 
(C)  Fluorescence microscopy image of microparticles scale bar is 20µm. 
(D)  TEM image of Qdots on glass scale bar is 50nm 
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Figure 5: An Intravital Microscopy Based Assay for Screening Nanoparticle 
Clearance Rates in Live Animals 
(A) A blood vessel is positioned in the center of the scan area. 
(B) A cartoon showing the orientation of the mouse, the positioning of the 
objective, and the region of the mouse ear imaged. 
(C) Movies are analyzed in ImageJ by selecting a straight line ROI in the large 
vein and average fluorescence intensity for each time point is calculated. Scale 
bar equals 50µm. 
(D) A representative fluorescence vs. time plot of nanoparticle clearance. Marked 
region represents the area under the curve, which is calculated to determine 
relative exposure to blood for particles. 
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As the clearance of nanoparticles is mediated by the phagocytic cells of 
the mononuclear phagocyte system (MPS), we depleted these cells from female 
BALB/c mice using liposomal clodronate (Clod) (Camilleri et al., 1995) and 
continuously measured the blood fluorescence over a two hour period in treated 
and untreated mice (Fig. 6A). As expected, plots of average fluorescence 
intensity over time show a greater peak fluorescence intensity and longer 
nanoparticle residency in blood for Clod- treated mice compared to untreated 
controls (Fig. 6B). To compare the relative exposure of nanoparticles to blood 
between the two conditions, the area under the curve was calculated (Fig. 6C) 
and showed a >6-fold increase of particle exposure to blood in Clod-treated mice. 
This experiment validated that IVM can be used to screen relative exposure of 
nanoparticles to blood.  
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Figure 6: Treatment of BALB/c mice with liposomal clodronate increases 
the circulation of nanoparticles in vivo. 
(A) Still images from a BALB/c mouse and a BALB/c mouse pre-treated with 
liposomal clodronate show significant differences in blood fluorescence from 
nanoparticles. Scale bar equals 50µm. 
(B) A plot of mean fluorescence intensity versus time shows the difference in 
particle clearance rates between the two conditions (N=4). 
(C) Plotting area under the curve shows a significant (p<0.003, t test) increase in 
fluorescence intensity in blood with clodronate pretreatment (N=4).  
 
 
Interestingly, we observed that in all BALB/c mice after a significant 
fraction of the particle dose had been cleared from the blood, areas containing 
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concentrated particles became visible. Upon careful observation, it became clear 
that these visible areas of fluorescence were cells and not extracellular 
aggregates of particles, as some of them moved in a random manner including 
some periods of persistent migration against the blood flow (Fig. 7). Based on 
observations from others, it is likely that these cells are a combination of 
neutrophils and peripheral monocytes (Auffray et al., 2007). This uptake of 
particles in the peripheral vasculature could explain the common finding across 
many nanoparticle studies that a significant fraction of the injected particle dose 
is not recovered from the exsanguinated blood and major organs (Vasquez et al., 
2011). Since a substantial proportion of blood vessel surface is left behind in the 
carcass and skin, particle clearance in the peripheral vasculature may account 
for some of the missing dose.  
 
Figure 7: Peripheral immune cells clear nanoparticles in the vasculature. 
Still images from representative movie (Sup. Movie 3) show the presence of 
three different types of cells made fluorescent by the uptake of labeled 
nanoparticles. White arrow indicates a cell that is free flowing in the blood and 
present for only a single frame of the movie, the red arrow shows a single 
randomly migrating cell and the yellow arrow shows a stationary cell. The 30 
minute max intensity projection shows that the migrating cell (red arrow) moved 
through a circuitous route including migrating against the blood flow. 
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Different mouse strains clear nanoparticles with different kinetics.  
 
The removal of nanoparticles from blood is mediated by the MPS system, 
and has been well studied on the cellular level by examining the role of various 
phagocytic receptors and endocytic/phagocytic mechanisms for particle uptake 
(Patel et al., 2010; Sahay et al., 2010; Yang et al., 2010). These properties of 
MPS cells are regulated at the level of the whole animal by higher order immune 
regulation mechanisms such as T-helper (Th) status(Martinez et al., 2006). 
However, the role of these global immune properties on nanoparticle clearance 
kinetics has been poorly studied. We examined the effect of Th1/Th2 immune 
priming in mice by measuring the blood exposure of nanoparticles in two Th1-
biased mouse strains (C57BL/6 and B10D2 (Mills et al., 2000)), two Th2-biased 
mouse strains (BALB/c and DBA/2 (Mills et al., 2000)), as well as BALB/c and 
C57BL/6 mice treated with Clod (Fig 8A). We observed that nanoparticle blood 
exposure was significantly higher in Th1-biased strains than in Th2-biased 
strains (Fig 8B, C), suggesting that clearance mechanisms differ according to 
mouse strain. Clod treatment increased blood exposure in BALB/c, but not the 
C57BL/6 strain (Fig. 8B, C), indicating that little MPS-mediated clearance occurs 
in the first two hours for Th1-biased strains. In addition, we consistently observed 
that the initial peak fluorescence for BALB/c mice was significantly lower than in 
all other strains. Clod treatment resulted in BALB/c peak fluorescence levels 
similar to that of other strains, indicating that this lower peak fluorescence was 
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due to the MPS. As peripheral immune cells containing particles were 
consistently observed to a greater extent in BALB/c mice compared to other 
strains tested, it is possible that peripheral clearance is stronger in BALB/c mice 
resulting in a significant amount of particles being cleared in the first pass 
through the circulatory system.  
 
Figure 8: Th1 mouse strains clear nanoparticles slower than Th2 strains.  
(A) Still images from supplemental movies 1-6 show the differences in particle 
circulation between the four mouse strains as well as liposomal clodronate pre-
treated BALB/c and C57BL/6 mice. 
(B) Plots of fluorescence intensity versus time for all four mouse strains and 
clodronate-treated mice (N=4 mice per condition). 
(C) Plots of area under the curve for all conditions show a significant (p<0.0001, 
One-way ANOVA Dunnett post-test) increase in blood fluorescence between 
BALB/c and C57BL/6 and B10D2 mice, but not DBA2. Clodronate treatment 
significantly increases  (p<0.003, t-test) blood fluorescence in BALB/c mice, but 
not C57BL/6. 
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To further address differences in clearance, we performed a biodistribution 
study by injecting BALB/c and C57BL/6 mice with particles and then sacrificing 
mice at 5min, 30min, 2hr and 24hrs post injection, followed by measuring 
fluorescence in homogenates of tissues by using a plate reader. Relative particle 
distribution was measured in the non-lymphoid organs (heart, lung, and kidneys 
(Fig. 9A)), lymphoid organs (spleen and liver (Fig. 9B)), whole blood (Fig. 9C), 
plasma (Fig. 9D), and blood cell fraction (red cells and leukocytes of whole 
blood) (Fig. 9E). Non-lymphoid organs showed low levels of particles at all time 
points, but C57BL/6 mice showed significantly higher levels of particles at 30min 
and 2hrs in heart and kidney, likely due to more particles still being present in 
blood contained in those organs. Spleen and liver showed a high level of particle 
uptake at all time points, with BALB/c mice having significantly more particles 
present at 5min, 30min and 2hrs. By 24hrs no significant differences were 
observed in any organ or compartment. Whole blood and plasma showed 
significantly more particles in C57BL/6 mice at 5min, 30min and 2hrs, but no 
significant difference was present by 24hrs. Blood cells showed significantly 
more particles in BALB/c mice at 5min and 30min, consistent with the IVM 
results. 
42 
 
 
 Figure 9: Biodistribution of 300nm PRINT hydrogel particles in Balb/c and 
C57BL/6 mice. 
(A) Distribution of particles in the lungs, heart, and kidneys of Balb/c and 
C57BL/6 mice. C57BL/6 mice showed significantly higher amounts of particle 
in heart and kidneys then Balb/c mice at 30min (P<.05 t-test), and 2hrs 
(P<.004 t-test) (N=4). 
(B) Distribution of particles in the liver and spleen of Balb/c and C57BL/6 
mice. C57BL/6 mice showed significantly lower amounts of particle present in 
both liver and spleen compared to Balb/c mice at 5min, 30min and 2hrs (P<.05 
t-test) (N=4). 
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(C) Relative amounts of particle present in Balb/c and C57BL/6 whole blood, 
C57BL/6 had significantly higher levels of particles in blood at 5min, 30min and 
2hrs compared to Balb/C mice (P<.05 t-test) (N=4). 
(D)  Relative amounts of particle present in Balb/c and C57BL/6 plasma, 
C57BL/6 had significantly higher levels of particles in blood at 5min, 30min and 
2hrs compared to Balb/C mice (P<.05 t-test) (N=4). 
(E) Relative amounts of particle present in Balb/c and C57BL/6 blood cell 
fraction of whole blood, C57BL/6 had significantly higher lower of particles in 
blood at 5min, and 30min compared to Balb/C mice (P<.05 t-test) (N=4). 
Some of the differential clearance of particles is due to uptake by 
granulocytes in Th2 prone strains. 
 
To further understand the differences in clearance of nanoparticles by Th1 
and Th2 prone mouse strains, we performed flow cytometry analysis of BALB/c 
and C57BL/6 peripheral blood leucocytes (PBL), splenocytes, and lymph nodes 
at 2hrs post injection. Lymph nodes were also assayed at 24hrs post injection to 
check for trafficking of phagocytes with particles to lymph nodes. We utilized a 
multi-marker flow cytometry protocol to determine particle uptake by lymphocytes 
(T and B cells), macrophages, monocytes, granulocytes, and dendritic cells 
(DC’s) (Fig, 10). Lymph nodes showed no particles present at 2hrs or 24hrs post 
injection (data not shown), suggesting that the PRINT particles used do not gain 
access to the lymphatic system after IV injection.  Uptake by T and B cells was 
minimal in both strains at 2hrs in blood and spleen, with no significant difference 
between strains (Fig. 11A). Uptake by DC’s was observed in the spleen in both 
strains at 2hrs, with C57BL/6 DC’s showing a significantly lower percentage of 
positive cells (Fig. 11B). Uptake by tissue macrophages (fully differentiated 
monocytes defined by the marker F480) showed no significant difference 
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between strains in the spleen (Fig. 11B). Surprisingly, uptake by monocytes in 
blood and spleen was significantly higher in C57BL/6 mice (Fig. 11A,B), but 
uptake by granulocytes was dramatically lower in both blood and spleen in 
C57BL/6 mice (Fig. 11A,B). These data suggest that some of the differential 
clearance observed between these mouse strains may be due to differential 
utilization of monocytes vs. granulocytes for particle uptake in the blood.  
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Figure 10.  Representative gating scheme from BALB/c mouse spleen. 
Single lymphocytes were gated by side scatter vs. forward scatter. Single cells 
were divided into B & T cells VS. non B & T cells by expression of CD3 and 
CD19.  For Non B & T cells those expressing high CD11b were selected for 
further analysis. CD11b high were plotted for F480 and GR1, GR1 high F480- 
were categorized as granulocytes, F480high GR1- were categorized as 
macrophages. GRI- F480- cells were further divided into monocytes (CD11c 
low), and DC’s (CD11c high). 
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 Figure 11: Flow cytometry of peripheral blood leukocytes and splenocytes 
shows dramatically higher uptake of particles by granulocytes in BALB/c 
mice. 
(A) Flow cytometry of PBL’s shows significantly higher uptake of particles by 
granulocytes in BALB/c mice (p<0.002, t-test), and significantly higher uptake by 
monocytes in C57BL/6 mice (p<0.05, t-test) (N=4). 
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(B) Flow cytometry of splenocytes shows significantly higher uptake of particles 
by DC’s (P< .05, t test) and granulocytes (p<0.003, t-test) in BALB/c mice while 
monocytes take up significantly more particles in C57BL/6 mice (p<0.05, t-test) 
(N=4). 
 
To address this idea directly, we depleted granulocytes from both strains 
by administering anti-Ly6-G antibodies, which has previously been shown to 
selectively deplete granulocytes in vivo (Arnold et al., 2010). Flow analysis 
confirmed that after antibody depletion, granulocyte numbers were reduced to 
below detection in both strains (Fig. 12). IVM was performed on both strains after 
granulocyte depletion to determine the effect on particle blood exposure. After 
granulocyte depletion, BALB/c mice showed equivalent peak fluorescence 
intensity compared to C57BL/6 mice (Fig. 13A), and a significant increase in 
particle blood exposure compared to untreated BALB/c mice (Fig. 13B). 
Conversely, C57BL/6 mice after granulocyte depletion showed no significant 
increase in peak fluorescence or particle blood exposure when compared to 
untreated C57BL/6 mice (Fig. 13B). These data indicate that some of the lower 
particle blood exposure (i.e., faster clearance) and lower peak particle 
concentration in BALB/c mice during the early passage through circulation is due 
to particle uptake by granulocytes in the blood. 
 
To determine the fate of particles in the blood and spleen in the absence 
of granulocytes, we assessed particle uptake by immune populations in 
granulocyte-depleted mice using flow cytometry.   Particle uptake by B and T-
lymphocytes of blood and spleen were unaffected (Fig. 13C,D); however, 
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increased particle uptake by blood monocytes was observed in granulocyte 
depleted BALB/c mice, but not in C57BL/6 mice (Fig. 13C). In the spleen, 
granulocyte depletion did not affect monocyte uptake, but did increase 
macrophage uptake, with a greater increase in the BALB/c mice (Fig. 13D). 
Together, these data indicate that granulocytes account for some of the 
increased clearance seen in the BALB/c mice, but that in the absence of these 
cells, BALB/c mice still clear nanoparticles faster than C57BL/6 mice. 
 
 
 
Figure 12: Depletion of granulocytes from mice using rat anti-mouse GR-1 
antibodies. 
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Figure 13: Depletion of granulocytes significantly increases particle 
exposure to blood in BALB/c mice but not C57BL/6 mice. 
(A) Plots of fluorescence intensity versus time for four BALB/c and C57BL/6 mice 
with and without monocyte depletion (N=4 mice per condition). 
(B) Plots of area under the curve show a significant increase in particle exposure 
to blood in BALB/c mice (p<0.01, One-way ANOVA, Dunnett post-test) but not 
C57BL/6 mice (N=4 mice per condition). 
(C) Flow cytometry analysis of changes in PBL particle distribution in BALB/c and 
C57BL/6 mice following granulocyte depletion.  BALB/c monocytes take up 
significantly more particles after granulocyte depletion (p<0.05, t-test) (N=3 mice 
for granulocyte depleted conditions and N=4 mice for controls). 
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(D) Flow cytometry analysis of splenocytes after granulocyte depletion in BALB/c 
and C57BL/6 mice. Macrophages in spleen take up significantly more particles 
after granulocyte depletion in both strains (p<0.05, t test) (N=3 mice for 
granulocyte depleted conditions and N=4 mice for controls). 
Differential clearance of particles in Th1 vs. Th2 strains is dependent on 
particle type.  
As a wide variety of nanoformulations are being investigated for potential 
clinical use and often demonstrate very different properties in vivo, we tested 
whether the differential clearance observed in various mouse strains is specific to 
the PRINT particles (300 nm, PEG hydrogel). We tested the blood exposure of 
quantum dots (Qdots) in BALB/c and C57BL/6 mice. The quantum dots were 
polymer coated with a carboxylated polymer that prevents aggregation in 
aqueous environments. The Qdots tested are a different class of nanoparticle 
(inorganic nanocrystal VS hydrogel) with a different surface (proprietary 
carboxilated polymer vs. PEG), a different shape (sphere vs. cylinder) and an 
order of magnitude smaller (avg size 30nm Qdots vs. 300nm cylindrical PRINT 
hydrogels (Fig. 4A-C). Upon IV injection, the Qdots were more rapidly removed 
from blood by both BALB/c and C57BL/6 mice than PRINT particles. However, 
the Th1 vs. Th2 biased strain clearance difference was still present (Fig. 14A, B), 
including a lower peak fluorescence intensity with Qdots, suggesting that a large 
number of Qdots are cleared in the periphery of BALB/c mice. To test if 
microparticles display the same effect in Th1 vs. Th2 strains, we utilized low 
elastic modulus PRINT microparticles (6 µm disks made of the same PEG 
hydrogel materials as 300nm cylindrical PRINT hydrogels) that were previously 
demonstrated to have long circulation times and are not cleared by mechanical 
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filtration in the lungs (Merkel et al., 2011). Interestingly, BALB/c and C57BL/6 
mice demonstrated the same microparticle exposure to blood (Fig 14C, D), 
suggesting that rapid removal of nanoparticles in Th2 prone strains is not 
observed with larger particles requiring phagocytic clearance.  
 
Figure 14: Depletion of granulocytes significantly increases particle 
exposure to blood in BALB/c mice but not C57BL/6 mice. 
 (A) Plots of fluorescence intensity versus time for quantum dots in blood of 
BALB/c and C57BL/6 mice show a similar trend to what was observed with 300 
nm PRINT hydrogel particles (N=4). 
(B) Area under the curve shows a significant (p<0.05, t-test) increase in blood 
fluorescence from quantum dots in C57BL/6 mice VS BALB/c mice. 
(C) Plot of fluorescence intensity in blood versus time for BALB/c and C57BL/6 
mice show similar clearance rates for microparticles. 
(D) Area under the curve analysis of blood fluorescence intensity from both 
strains shows no significant difference. 
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Murine bone marrow derived macrophages and primary human peripheral 
blood monocyte-derived macrophages take up more particles with M2 
polarization.  
 
We examined if differential clearance by Th1 and Th2 prone strains can 
be reproduced in vitro by culturing primary bone marrow derived macrophages 
(BMM) from both strains and testing particle uptake by BMMs. We chose to use 
BMMs as opposed to granulocytes due to the fact that BMMs can be maintained 
in culture for longer time periods, thus allowing treatment with Th1 and Th2 
cytokine mixtures to polarize these macrophages towards M1 or M2 phenotypes, 
respectively. We imaged the accumulation of particles inside the macrophages 
and quantified the integrated fluorescence intensity of particles per cell. We also 
processed cells for analysis by flow cytometry. Consistent with our in vivo 
observations, untreated BALB/c macrophages take up significantly more particles 
than untreated C57BL/6 macrophages in vitro as assayed by both confocal 
microscopy and flow cytometry (Fig. 15A, B). BMMs from both strains were also 
directed towards M1 or M2 polarization by specific mixtures of cytokines and 
immune stimulators (see Materials and Methods). M1 polarization of C57BL/6 
macrophages had no effect on particle uptake, while differentiation into the M2 
phenotype resulted in an increase in particle uptake (Fig. 15A, B). Conversely, 
M1 polarization of BALB/c macrophages reduced particle uptake to the same 
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level as C57BL/6 macrophages, while M2 polarization showed no significant 
difference compared to BALB/c control (Fig. 15A, B). 
 
As significant differences are known to exist between mouse and human 
macrophages (Mestas and Hughes, 2004),we repeated particle uptake 
experiments with human monocyte-derived macrophages from two healthy 
human volunteers. Volunteer A’s macrophages showed high uptake of particles 
with no stimulation, a significant reduction in uptake with M1 polarization, and no 
difference with M2 polarization (Fig. 15C). Volunteer B’s macrophages showed 
intermediate uptake of particles with no stimulation, a significant decrease in 
uptake with M1 polarization, and a significant increase in uptake with M2 
polarization (Fig. 15D).  These results confirm that immune polarization 
fundamentally impacts cellular interactions with nanoparticles in human cells. 
 
One significant difference between M1 and M2 macrophages is that M2 
macrophages are known to express higher levels of many different scavenger 
and lectin receptors than M1 macrophages. Flow cytometric analysis of revealed 
increased MMR (macrophage manose receptor) expression on the surface of 
BALB/c macrophages (BMMs) compared to C57BL/6 macrophages (Fig. 15E), 
which is consistent with previously published transcriptional profiling data (35,38). 
To test whether the differential uptake of particles by BALB/c and C57BL/6 
macrophages is MMR-dependent, we treated with BMMs with the competitive 
MMR inhibitor mannan prior to addition of particles. Mannan reduced particle 
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uptake in BALB/c macrophages to the same level as C57BL/6 macrophages 
while showing no effect on C57BL/6 macrophages, suggesting that the increased 
level of MMR present on M2 macrophages in BALB/c mice may contribute to  
differences in particle uptake in vitro (Fig. 15F) and (Fig 16).  
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Figure 15: M2 polarized macrophages take up more particles than M1 
macrophages in mice and humans.  
(A) Average integrated fluorescence per cell showed a significant (p<0.0001, 
One-way ANOVA Dunnett’s post-test) increase in particle uptake by BALB/c 
untreated, BALB/c Th2-treated, and C57BL/6 Th2-treated VS C57BL/6 untreated 
cells. C57BL/6 M1-treated and BALB/c M1-treated showed no significant 
difference vs. C57BL/6 untreated Cells (N=4).  
(B) Flow cytometry analysis of uptake showed a significant (P<0.05, One-way 
ANOVA Dunnett’s post-test) increase in uptake by BALB/c untreated, BALB/c 
Th2-treated, and C57BL/6 Th2-treated VS C57BL/6 untreated cells. C57BL/6 
M1-treated and BALB/c M1-treated showed no significant difference vs. C57BL/6 
untreated cells (N=4).  
(C) Flow cytometry analysis of uptake by human macrophages from volunteer A. 
M1 macrophages took up significantly less particles than control or M2 
macrophages (P<0.0001, One-way ANOVA Dunnett’s post-test) (N=4). 
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(D) Flow cytometry analysis of uptake by human macrophages from volunteer B. 
M1 macrophages took up significantly less than control macrophages (P<0.0001, 
One-way ANOVA Dunnett’s post-test). M2 macrophages took up significantly 
more than control macrophages (P<0.001, One-way ANOVA Dunnett’s post-test) 
(N=4). 
(E) Flow cytometry analysis of surface MMR expression on Balb/c and C57BL/6 
mice. Balb/c mice showed significantly higher surface expression of MMR 
(P<0.05, t-test) (N=4). 
(F) Microscopy analysis of uptake by BMMs after mannan blocking. Addition of 
Mannan reduced uptake by Balb/c macrophages to the same levels as C57BL/6 
controls (P<0.0001, One-way ANOVA Dunnett’s post-test)(N=4). 
(G) Representative flow cytometry histogram of particle uptake by BALB/c and 
C57BL/6 BMM’s. 
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Figure 16: Confocal microscopy of Balb/c and C57BL/6 BMMs with and 
without mannan treatment. 
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DISCUSSION 
 
In this study, we have identified a striking difference in nanoparticle 
clearance in different strains of mice that arises due to differences in global 
immune status differences. Th1-prone strains such as C57BL/6 clear particles 
more slowly and have a higher blood exposure compared to the Th2-prone 
BALB/c strain that demonstrated rapid particle clearance. Both 
monocytes/macrophages and granulocytes in the peripheral vasculature and 
spleen are responsible for clearance differences between the strains. 
Interestingly, the differences in clearance were recapitulated in vitro using 
mouse and human macrophages treated with either Th1 or Th2 
chemokine/cytokine mixtures. This effect may be due, in part, to differences in 
surface expression of scavenger receptors such as the macrophage mannose 
receptor (MMR).   
 
In most studies nanoparticle PK is determined by blood draws at specific 
time points post injection, combined with appropriate assays for determining the 
particle concentration in blood (Chu et al., 2012; Kulkarni and Feng, 2013). This 
method has the advantage of directly measuring the particle itself rather than a 
reporter probe and provides absolute particle concentration in the blood. 
However, this approach requires large numbers of animals and particles to yield 
useful data. Most experiments of this type require four animals or more per time 
point, and at least five time points plus a control for a minimum of 24 animals 
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needed for each condition tested. This makes blood draw assays an 
unattractive option for screening multiple types of animals and/or particle types 
due to the high time and resource investment required. In addition, blood draw 
PK tends to give very limited temporal resolution, usually seven or fewer points 
per 24hr experiment (Caron et al., 2012).  
 
Intravital microscopy (IVM) has a number of advantages for measuring 
nanoparticle clearance. With IVM, the relative amount of particles in the 
bloodstream is measured with a wide dynamic range allowing for 
measurements spanning pre-injection to peak particle concentration through 
clearance in a single animal. Fluorescent probes can be directly incorporated 
into hydrogel nanoparticles during synthesis, therefore eliminating the need for 
extensive post-fabrication modifications. In addition, this technique is very fast, 
allowing for real time or near real time measurement of relative particle 
concentrations. Finally, IVM can be multiplexed with different fluorescent dyes 
coupled to different particle types or formulations to measure differential 
clearance in the same animal. However, IVM is limited by the fact that only 
relative numbers are readily available from this type of experiment, the particle 
must be fluorescent, and it is difficult to run experiments longer than 3hrs due to 
the stress on the animal from extended anesthesia.  
 
The nanoparticle research field operates under the implicit assumption 
that nanoparticles will circulate in similar ways in all strains of mice. We are 
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unaware of any previous study that has directly compared the effect of mouse 
strain on nanoparticle circulation times. Our results indicate mouse strain 
background is a critical factor for nanoparticle clearance and is likely important 
for the interpretation of all results of nanomedicine studies. In fact, the changes 
in circulation times observed between Th1 and Th2 prone mouse strains is 
equivalent to the changes that can be produced by heavily PEGylating particle 
surfaces (Perry et al., 2012). This demonstrates that changes in the immune 
status of patients and experimental animals may affect nanoparticle PK to at 
least the same degree as the material properties of particles. However, far less 
work has been done studying the effects of biology on nanoparticle PK than the 
effects of material properties on nanoparticle PK. It is perhaps not surprising 
that we see different results in different mouse strains for clearance, as mouse 
strain background has significant impact on biological processes ranging from 
immune function (Kastrukoff et al., 2012), pain sensation (Mogil et al., 1999) 
and cancer (Mesquita et al., 2012). Outbred, wild mice show a large degree of 
heterogeneity in many measures of immune function, while inbred lab strains of 
mice show very little intrastrain variation (Abolins et al., 2011). In the future, it 
would be beneficial for researchers in the nanoparticle field to begin explicitly 
considering mouse strain immunology when designing experiments and 
interpreting data. 
 
Based on our results, global immune system regulation has a significant 
role in nanoparticle clearance. One main global immunological difference is Th1 
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vs. Th2 status. Numerous studies have established that Th1 and Th2 cytokines 
can induce macrophage differentiation into the corresponding M1 and M2 
phenotypes (Gordon and Martinez, 2010). The result that Th1 prone mice (eg. 
C57BL/6) clear nanoparticles slower is somewhat surprising as M1 
macrophages are thought to be more inflammatory, involved in the destruction 
of pathogens, and have been shown to be more phagocytic towards S. aureus 
(Krysko et al., 2011). The M2 macrophages prevalent in the fast clearing Th2 
stains are generally thought to be anti-inflammatory, with involvement in wound 
healing and potentially less phagocytic (Gordon and Martinez, 2010). However, 
M2 macrophages are thought to have higher levels of endocytosis and may 
thereby take up small particles rapidly. In addition, M2 macrophages are known 
to express higher levels of scavenger and lectin receptors that could be 
responsible for the increased clearance (Martinez et al., 2006). Our data on the 
elevated surface expression of MMR on M2 macrophages and the reduced 
nanoparticle uptake upon mannan treatment support this notion.  
 
While the addition of mannan blocks the enhanced uptake of PEG 
hydrogel particles in M2 macrophages in vitro, a baseline uptake of particles still 
occurs with treatment. Indeed, clearance in vivo likely involves multiple 
receptors and mechanisms. Determining which receptors are responsible for 
nanoparticle clearance is an important next step. Unfortunately, the obvious 
genetic approach of using knockout mice (KO) in candidate clearance receptors 
is severely complicated by the fact that most of these KO’s exist only in the 
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C57BL/6 strain. Since treatment of the slow-clearing C57BL/6 mice with 
clodronate liposomes (removing all MPS cells) did not show a statistically 
significant increase in nanoparticle circulation times in a 2hr window, it is 
unlikely that the genetic loss of any single candidate clearance receptor would 
produce a measurable decrease in nanoparticle clearance. In the future, it will 
be essential to backcross these KO’s into the BALB/c background where these 
experiments are likely to produce more informative results. 
  
It is also worth considering the role of granulocytes (primarily neutrophils) in 
nanoparticle clearance. Although this cell type is rarely discussed as an MPS 
cell (Rabinovitch, 1995; Silva and Correia-Neves, 2012), our data clearly 
indicates that granulocytes play a significant role in the differential nanoparticle 
clearance observed between mouse strains. Previous reports indicate that 
BALB/c mice have greater numbers of circulating granulocytes than C57BL/6 
mice (Petkova et al., 2008). Our data indicate that mere differences in 
granulocyte numbers are unlikely to account for the clearance differences 
between strains, as a smaller percentage of C57BL/6 granulocytes take up 
particles than BALB/c granulocytes. Since neutrophils constitute a large fraction 
of circulating white blood cells in humans (Bishton and Chopra, 2004) and 
neutropenia is a common side effect of clinical treatments such as 
chemotherapy, it will be important to further explore the role of neutrophils in 
nanoparticle clearance in future studies.  
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Similar to our results with mice, the pharmacokinetics of nanoparticles is 
highly variable in human patients (Caron et al., 2012). Previous studies 
demonstrated that monocyte function, as assayed by phagocytic capacity and 
oxidative burst, can be used to predict the clearance of liposomal Doxil (Caron 
et al., 2012). Since both the phagocytic capacity and oxidative burst are partially 
controlled by the patient’s global immune status (Mills et al., 2000), it is likely 
that the Th1/Th2 balance is an important factor in human nanoparticle 
clearance as well. This is supported by our results with human macrophages 
that showed a significant decrease in particle uptake from both volunteers’ 
macrophages following M1 polarization, and one volunteer’s macrophages 
showing an increase in uptake with M2 polarization.  Future studies are needed 
to explore the role of previous immune priming events such as infections or 
allergies on nanoparticle clearance. Our data suggest that a more 
comprehensive understanding of how global immune regulation affects 
nanoparticle clearance will be important both for nanoparticle studies in animals 
and eventual clinical use. 
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CHAPTER FOUR: FUTURE DIRECTIONS 
 
 The nature of the interactions between nanoparticles and the immune 
system still requires significant study to be fully understood, appreciated and 
manipulated. The work presented here suggests promising avenues to be 
pursued and provides several valuable tools to use in future work. In this 
chapter I will address some, although certainly not all, possible future work that 
can derived from the foundation of this body of work. 
 
Genetic Factors Controlling Th1/Th2 Polarization and Nanoparticle 
Clearance 
 This work has shown a clear correlation between Th1 and Th2 immunity 
and particle clearance. However it also suggests that the relationship may be 
more complicated than a simple interpretation of Th2 cytokines produce M2 
macrophages which clear particles more rapidly than M1 macrophages. Three 
results in particular suggest a more complex explanation is needed to fully 
explain the above results. First, non-diseased mice have cytokine levels that 
are extremely low or below detection.This means that resting macrophages in 
these mice should be relatively non-polarized towards either M1/M2 activation 
states. Secondly, isolated primary macrophages from BALB/c and C57BL/6 
mice show a difference in particle uptake with no additional cytokine treatments 
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after identical treatment with L-media and serum which contain the same base 
line of cytokines. This suggests that there is some type of basal genetic 
difference between BALB/c and C57BL/6 macrophages that, while correlated 
with Th1/Th2 prone states, exists independent of cytokine stimulation. Finally, 
the dramatic difference observed in neutrophil activity towards particles in 
BALB/c vs C57BL/6 suggests that differences between Th1 and Th2 cytokine 
activity is not the entire story, as short lived neutrophils in healthy mice will have 
seen very little in the way of cytokines during their life cycle. These three data 
points suggest that there is some upstream genetic difference causing the 
Th1/Th2 polarization, the differences in particle uptake by unstimulated 
macrophages, and the differences in particle uptake by neutrophils. 
Determining what this driving genetic difference is could both reveal important 
aspects of how the immune system interacts with nanoparticles, as well as 
important genetic regulation of Th1/Th2 immunity and its relationship to innate 
immunity.  
 A likely way to address this is using the collaborative cross mice 
(Churchill et al., 2004). The collaborative cross was performed by taking a 
number of lab mouse strains and wild caught mice from around the world and 
breeding them together for several generations before deriving a large number 
of new inbreed strains, with each of these new strains being exhaustively 
genetically profiled at the sequence and transcriptome level. By combining this 
model set with the intravital microscopy PK assay described in this work we 
would have an excellent chance at determining what alleles are responsible for 
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slow and fast nanoparticle clearance by determining which collaborative cross 
strains clear faster or slower, and grouping these datasets. This can then be 
followed by in depth genome and transcriptome analysis to determine which 
alleles are consistently altered in fast and slow clearing mice. Determining 
which genetic pathways are consistently changed in fast vs slow clearing mice 
may allow us to both predict candidate receptors on macrophages and 
neutrophils which could be blocked to extend clearance, or pathways which 
could be drugged to extend particle circulation.  
 
Determination of Gene Products Controlled by Th1/Th2 Cytokines That 
Clear Nanoparticles 
 Ultimately the most likely way to extend the circulation time of 
nanoparticles in vivo is to block the receptors on macrophages that bind and 
clear particles. This is preferential to drug treatments that inactivate phagocytes 
as it will have fewer off-target effects and leave patients less immune 
suppressed. However in order to generate function blocking antibodies or FAB 
fragments against the relevant phagocytic receptors we must first positively 
identify which receptors mediate nanoparticle clearance. We anticipate that this 
can be accomplished in mice using two approaches. First we will need to isolate 
some combination of macrophages, neutrophils and monocytes from BALB/c, 
DBA2, C57BL/5 and B10D2 mice. From these cells RNA can be extracted and 
analyzed by RNA deep sequencing technology to generate an accurate 
transcriptome of each of these cell populations from each mouse type. The 
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same can be done on BALB/c and C57BL/6 BMM’s either untreated or treated 
with cytokines. These samples can then be grouped into two distinct 
populations of cells that take up large numbers of particles and cells that do not. 
We can then analyze the transcriptomes of these cells and determine which 
specific phagocytic receptors have been up regulated in the fast clearing cells 
versus the slow clearing cells. Any receptors that are consistently up in fast 
clearing cells can then be confirmed by quantitative PCR analysis and Western 
to ensure that they represent genuine targets.  
 After determining what receptors are consistently expressed at higher 
levels on phagocytes that clear particles rapidly we can purchase mice that 
have had the receptors knocked out in most cases. Unfortunately these 
receptors are typically knocked out in C57BL/6 mice, which means to use our 
IVMPK assay we must back cross them onto a BALB/c background.  This will 
take approximately two years two accomplish, and so should only be performed 
for receptors that have been implicated by the genetic approaches above. But 
once the backcross is complete we can analyze particle circulation times by 
IVMPK to determine the relative impact of each receptor type on particle 
clearance. 
 Finally for any receptors that have been confirmed to be relevant for 
clearing nanoparticles in knockout mice, we can either purchase or generate 
function blocking antibodies or FAB fragments against them. These can then be 
administered prior to nanoparticle injection to block particle uptake and confirm 
the functionality of inhibiting the implicated receptors. Any receptors that show 
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positive effects from being blocked can be considered for the generation of anti 
human function blocking antibodies for evaluation in the clinic for extending the 
circulation time of nanoparticles in patients. 
 
Further Elucidation of Th1/Th2 Effects on Nanoparticle Clearance 
 As discussed above it is unlikely that Th1/Th2 immune status is the sole 
driver in the differential clearance we observed in this study. However the in 
vitro data clearly demonstrates that Th1/Th2 cytokines can affect the clearance 
of nanoparticles by primary human and mouse macrophages. It is therefore 
worth further elucidating this response in vivo using several common 
immunological assays. 
 First, our data clearly shows that BMM’s from BALB/c and C57BL/6 mice 
have differential particle uptake phenotypes independent of cytokines and T cell 
signals. However it is unclear if this is due to activity of T cell cytokines earlier in 
the development of these cells in mice, or due to inherent genetic differences in 
the macrophages themselves. To test we can first examine the clearance of 
nanoparticles in several mouse models with modified T cell characteristics. 
Nu/Nu mice that lack proper thymuses and therefore lack T cells can be 
purchased in both the BALB/c and C57BL/6 background allowing us to 
determine if clearance of particles in vivo is altered by the loss of T cells in 
these mice. In addition Rag-/- BALB/c and C57BL/6 mice are available that 
have proper thymuses, but do not result in adult T cells in vivo, these mice can 
be compared to wild type and Nu/Nu mice to determine if mature T cells, 
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immature T cells, or no T cells are required for the observed differences in 
nanoparticle circulation. Additionally in all of these models Th1 or Th2 T cells 
from background matched wild type mice can be transferred into the T cell 
deficient mice to see if this can rescue/change observed particle uptake 
phenotypes. These experiments should allow us to determine the relative 
impact on T cell signaling versus genetic differences in other cell types in the 
mouse on particle uptake. 
 Second while BALB/c and C57BL/6 mice are known to be Th1/Th2 prone 
these are not true Th1/Th2 immunity models as cytokine levels remain low. It 
would therefore be better to test the effect of Th1 and Th2 immunity on particle 
clearance in disease models that are well characterized to generate these 
responses. To do this we would first determine the base circulation profile in the 
C3H/HeN mouse strain which is capable of having either a Th1 or Th2 immune 
response. After determining the basal clearance of particles we can infect 
another group of HEN mice with helminth parasitic worms which are well 
characterized to generate Th2 immune responses, and or induce experimental 
asthma which is also know to involve Th2 responses. A second group can be 
infected with gram positive bacteria and or yeast infection to induce Th1 
immune responses. We can then determine the effect of these treatments on 
clearance of particles both during and after the immune response to see if 
particle clearance is affected as expected in both the short term and the long 
term by Th1/Th2 immunity. 
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 Finally, to examine the effect of stromal cells versus immune cells on 
particle clearance BALB/c and C57BL/6 mice can be irradiated to kill all bone 
marrow. After irradiation, bone marrow transplantation can be performed with 
strain matched or reversed bone marrow. This will be followed up with multiple 
rounds of clodrinate injections to remove tissue macrophages from the original 
bone marrow. If BALB/c mice with BALB/c bone marrow and C57BL/6 mice with 
BALB/c bone marrow clear particles rapidly while C57BL/6 mice with C57BL/6 
bone marrow and BALB/c mice with C57BL/6 bone marrow clear particles 
slowly this indicates that differences in the immune system are responsible for 
the observed differences in particle uptake. If, however, the opposite were 
observed, it would suggest that signaling contributions from the stromal cells 
early in phagocyte differentiation are instead responsible for establishing the 
observed differences in particle clearance. 
 Combining these three experiments together should result in a much 
more complete understanding of the exact role of Th1/Th2 immunity on particle 
clearance. 
 
 
Clinical Studies 
 In this work we demonstrated that with a limited sample (N=2) human 
primary blood monocyte derived macropahges behaved similarly to mouse 
macropahges in regards to particle uptake with M1/M2 polarization. However 
there was a substantial difference in the base line uptake of particles by 
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macrophages from the two volunteers. As the value of this work is ultimately to 
improve the efficacy of nanomedicine in human patients it will be important to 
expand on these preliminary experiments with human cells in three ways. First 
and most simply, we need to test a much larger number of human samples. 
This should be done by drawing blood from 20-30 individuals; part of it should 
be used to derive macrophages as done in this study and test baseline uptake 
of particles and the effect of Th1/Th2 cytokine treatment on particle uptake.  
Secondly, we will also dose sample of whole blood from each volunteer with 
particles and then perform flow cytometry on it. This will allow us to determine if 
we see significant differences in the capacity of neutrophils from the different 
volunteers to uptake particles the same way we see differences with different 
mouse strains. Finally we will run ELISA assays for Th1 and Th2 cytokines on 
the plasma from the blood samples and look for correlations between uptake by 
primary macrophages and by neutrophils in whole blood samples to levels of 
Th1 and Th2 cytokines from volunteers.  After establishing baseline readings 
from healthy human volunteers we can get blood samples from clinical patients 
who are experiencing pathological conditions known to elicit Th1, Th2 or Th17 
immune responses. Examples can include asthma or severe allergies for Th2, 
bacterial or yeast infections for Th1, or severe viral infections or autoimmune 
conditions for Th17. These samples can then be analyzed in the same way as 
the healthy volunteer’s samples to determine if the anticipated changes in 
phagocyte behavior from the mouse studies are seen in human samples. 
Finally, there are large numbers of ongoing clinical trials for a diverse range of 
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nanoparticles as well as patients being treated with the approved 
nanoformulation Doxil. We can acquire blood samples from these patients as 
well as detailed PK results from these patients in clinical studies. We can then 
analyze the blood from the patients for levels of Th1 and Th2 cytokines and 
phagocyte behavior and determine how this correlates to observed PK data in 
patients. We predict that we will be able to determine appropriate assays for 
cytokine levels to predict if patients being treated with nanoparticles are likely to 
clear particles quickly or slowly.  In addition if we experience success with 
identifying important receptors in clearance and generating function blocking 
antibodies against them, then in the distant future we may be able to alter the 
PK of nanoformulations in patients with these reagents. 
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APPENDIX A: 
MATERIALS AND METHODS: 
Particle Materials and Methods:  
Materials 
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoethyl 
methacrylate hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine 
oxide (TPO),  and sucrose were purchased from Sigma-Aldrich. Thermo 
Scientific Dylight 650 maleimide, PTFE syringe filters (13 mm membrane, 0.22 
µm pore size), and methanol were obtained from Fisher Scientific. Conventional 
filters (2 μm) were purchased from Agilent and polyvinyl alcohol (Mw 2000) 
(PVOH) was purchased from Acros Organics. PRINT molds (200 nm x 200 nm) 
were obtained from Liquidia Technologies. Tetraethylene glycol monoacrylate 
(HP4A) was synthesized in-house. 
 
PRINT Nanoparticle Fabrication 
The pre-particle solution was prepared by dissolving 5 wt% of the various 
reactive monomers in methanol. The reactive monomers included: a cure-site 
monomer (an oligomeric PEG with a nominal molar mass of 700 g/mol 
terminally functionalized on both end groups with an acryloxy functionality), a 
hydrophilic monomer used to make up the majority of the particle composition 
(HP4A), a polymerizable fluorescent tag (Dylight  650 maleimide), and a 
photoinitiator. The pre-particle solution was comprised of 87.5 wt% HP4A, 10 
wt% PEG700DA, 1.5 wt% Dylight 650, and 1 wt% TPO. Using a # 3 Mayer rod 
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(R.D. Specialties), a thin film of the pre-particles solution was drawn onto a roll 
of freshly corona treated PET using a custom-made roll-to-roll lab line (Liquidia 
Technologies) running at 12 ft/min. The solvent was evaporated from this 
delivery sheet by exposing the film to a hot air dam derived from heat guns. The 
delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned side of the 
mold, followed by delamination at the nip. Particles were cured by passing the 
filled mold through a UV-LED (Phoseon, 395 nm, 30 PSI N2, 12 ft/min). A 
plasdone harvesting sheet was hot laminated to the filled mold (140ºC, 80 PSI, 
12 ft/min). Upon cooling to room temperature, particles were removed from the 
mold by splitting the harvesting sheet from the mold.  Particles were then 
harvested by dissolving the plasdone in a bead of water (1 mL of water per 5 ft 
of harvesting sheet). The particle suspension was passed through a 2 µm filter 
(Agilent) to remove large particulates. To remove the excess plasdone, particles 
were centrifuged at ca. 21,000 x g for 15 min, the supernatant was removed 
and the particles were re-suspended in sterile water. This purification process 
was repeated 4 times.   
 
Nanoparticle Characterization  
Stock particle concentrations were determined by thermogravimetric analysis 
(TGA) using a TA Instruments Q5000 TGA. TGA analysis was conducted by 
pipetting 20 µL of the stock particle solution into a tared aluminum sample pan. 
Samples suspended in water were heated at 30°C/min to 130°C, followed by a 
10 minute isotherm at 130°C.  Samples were then cooled at 30°C/min to 30°C, 
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followed by a 2 minute isotherm at 30°C. TGA was also performed on a 20 µL 
aliquot of supernatant from a centrifuged sample of the stock nanoparticle 
suspension to account for the mass of any stabilizer remaining in each sample. 
The supernatant concentration was subtracted from the concentration of stock 
particle suspension to determine the actual particle concentration.  Particles 
were visualized by scanning electron microscopy (SEM) using a Hitachi S-4700 
SEM. Prior to imaging, SEM samples where coated with 1.5 nm of gold-
palladium alloy using a Cressington 108 auto sputter coater. Particle size and 
zeta potential were measured by dynamic light scattering (DLS) on a Zetasizer 
Nano ZS (Malvern Instruments, Ltd.). 
 
Microparticle Fabrication 
PRINT molds made of perfluoropolyether were received from Liquidia 
Technologies (NC, USA). The RBC mimics--starting from a pre-polymer 
composition of 87% 2-Hydroxyethyl acrylate (sigma), 10% 2-Carboxyethyl 
acrylate (sigma), 1% Poly(ethylyeny glycol) diacrylate (MW=4,000) 
(PolySciences), and 1% DyLight 650 malemide (ThermoScientific)--were made 
using a mold that had discoid feature with 2 μm diameters and heights of 0.6 
μm. Briefly, the pre-polymer mixture was spread onto a piece of the mold 
(0.5×0.5 ft.) that was chilled to 2-5°C on a custom-built laminator platform to 
avoid monomer evaporation prior to photocuring. A poly(ethylene terepthalate) 
(PET) sheet was laminated to the top of the mold and pre-polymer solution, 
wetting the total mold area. The sheet was peeled away at the nip point of the 
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laminator, leaving the wells of the mold filled while wicking away excess 
solution. The filled mold was immediately transferred into a chilled (2–5 °C) 
nitrogen purged UV oven and cured with UV light (λ=365 nm, power =20 
mW∕cm2) for 3 min. After curing, the filled mold was placed face down on a thin 
film of 0.1% 2,000 g/mol poly(vinyl alcohol) (PVOH, Acros) in water on top of 
another PET sheet. This assembly was placed in a cooler filled with dry ice, 
allowing the water to freeze and adhere to the particles. After freezing, the mold 
was peeled away from the particles trapped in the ice layer, and the ice was 
allowed to melt. RBCMs and water were collected, washed, and concentrated 
via centrifugation at ca. 21,000 x g (Eppendorf 5417R) to remove any sol 
fraction from solution. Particles were then suspended in 0.1% 2,000 g/mol 
PVOH in PBS, pH 7.4 for subsequent experiments. 
 
Intravital Microscopy. Intravital microscopy experiments were performed using 
an IV-100 laser scanning microscope (Olympus) on female mice of 19- to 24-g 
body weight. BALB/c (Charles River), C57BL/6, DBA/2, and B10D2 (Jackson 
Labs) were maintained in clean animal housing at UNC. Hair was removed from 
the ear, and a tail vein catheter was applied. The mice were anesthetized with 
isofluorane and placed onto a heated stage (37°C), with their ear immobilized 
by two sided taping to an aluminum block. Blood vessels were located by 
illuminating the ear with a bright white light while imaging in the green 
fluorescence channel. Blood vessels appear dark on the field. A suspension of 
300 nm PRINT particles, 15 mg particles/kg mouse weight via a 4 mg/mL 
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solution of particles in isotonic 9% sucrose solution, was then injected and 
visualized using a 633-nm laser. For all imaging blood vessels were selected 
from the approximate same region of the ear to reduce differences in intensity 
due to depth of the vessel. For experiments with liposomal clodronate mice 
were injected with 100 µl of 5 mg/mL clodronate in liposomes both IV and IP 24 
hrs prior to experiments. Clodronate was purchased from Encapsula, Nashville 
TN. For microparticle injections 15 mg/kg of particle in a 2 mg/ml PBS 
suspension was used. For quantum dot experiments a 4 nmol water soluble 
carboxilated 665-nm emission suspension of qdots were purchased from Ocean 
NanoTech (Springdale, Arkansas). 5µl of Qdots were suspended in 100 µl of 
PBS and then IV injected via tail vein. Granulocyte depletion was performed by 
injecting 1mg of rat anti mouse Ly6-G (GR-1) monoclonal antibody 1a8 
(bioXcell USA) IP 3 days and 1 day prior to experiments. 
 
For image analysis of the blood exposure of the particles, the image files from 
each scan were exported to ImageJ. For ease of analysis, we followed the 
example of Merkel et al. (Merkel et al., 2011) and stacked the images in groups 
of 5. We analyzed the region of interest containing vasculature for fluorescent 
signal prior to particle injection, and in each scan after injection. The 
background fluorescence value prior to injection was then subtracted from all 
following fluorescence values. The data was then exported to GraphPad Prism 
to generate graphs and perform indicated statistical analysis.  
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Biodistribution. BALB/c and C57BL6 mice were injected with 300nm 
cylindrical PRINT particles as described above. At 5min, 30min, 2hr, and 24hrs 
after injection, four mice of each strain were sacrificed by CO2 asphyxiation 
followed by cardiac puncture to collect blood. The lungs, kidneys, heart, liver 
and spleen were collected and kept in PBS on ice. Solid organs were weighed 
then placed in 2X weight volume of PBS. The organs were then homogenized 
and PBS was added to each tube to bring it to a known volume. 50µL of organ 
homogenate was pipetted into a 96 well plate. For blood 50µL of whole blood 
was plated followed by centrifuging the remaining blood for 5min at 1500RPM 
to separate plasma and blood cells. 50µL of plasma and cell fraction was then 
plated. The plates were read using a fluorescent plate reader (BD, USA), and 
fluorescence values per gram of tissue were calculated. 
 
Flow cytometry of animal samples. Blood was collected by cardiac puncture 
and added to EDTA tubes.  Spleen and inguinal lymph nodes were dissected 
and placed in FACS buffer (1xPBS +5%FCS) on ice. All samples were kept on 
ice or at 4°C for the duration of the experiment. 300µl of blood was taken from 
each sample; red cells were lysed by addition of 2ml of 0.1X PBS for 10sec 
followed by 2ml of 2X PBS and 10ml FACS buffer. Spleen and lymph nodes 
were gently dissociated between frosted slides to free cells and filtered through 
70µm cell filters. Red cells in spleen samples were lysed by addition of 1ml 
ACK lysis buffer (Gibco, Grand Island, NY USA) for 1 min followed by 14ml 
FACS buffer. Cells were blocked with  anti-CD16/32 (Fc-block) from BioLegend 
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(San Diego, CA USA)) 2µl per sample in 10µl for 10min. Mouse cells were then 
stained with the following  antibodies; anti-CD3-FITC (145-211C), CD19-FITC 
(ebio1D3), CD19-efluor450 (ebio1D3),  anti-TCRβ-APC-Cy7 (H57-591) from 
ebioscience (San Diego, CA USA),  anti-CD11c-PacBlue (N418), anti-F4/80-PE 
(CI:A3-1), CD11b-PE-Cy7 (M1/70), anti-Gr-1-APC-Cy7 (1A8) from BioLegend 
(San Diego, CA USA), and anti-CD45-PacOrange (MCD4530) from Invitrogen 
(Grand Island, NY USA).  Cells were stained using antibodies at 1: 200 for 
30min on ice. Cells were fixed using 2% PFA in PBS.  Particle fluorescence in 
BMM was detected in the far red channel with a 633nm laser. The average 
fluorescence intensity of live single cells was calculated and reported. All data 
were collected using LSRII (BD Biosciences, San Jose, CA USA) or CyAn 
(Beckman Coulter, Brea, CA  USA) flow cytometers.  Data analysis performed 
using FlowJo software (Treestar, Ashland, OR USA). 
Cell Culture Reagents. BMM’s were generated by extracting bone marrow as 
described previously (Bennett, 1966) from four female BALB/c or C57BL/6 mice 
and differentiated into macrophages using L-media as previously reported 
(Englen et al., 1995). After 1 week of differentiation, cells were placed in serum 
free DMEM media (Sigma). Cells were then washed once with PBS, placed in 
ice cold PBS + 5% FBS + .5 mM EDTA, and left on ice for 10 min. Cells were 
then lifted by gentle scraping and pelleted by centrifugation. 350,000 
macrophages were then plated on glass coverslips in DMEM supplemented 
with 10% FBS (HyClone USA), L-Glutamine, and penicillin/streptomycin for 
microscopy, or plated under the same media conditions in a 24 well plate for 
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flow cytometry experiments. For cytokine stimulation, we followed a previously 
published protocol for in vitro differentiation of macrophages (Martinez et al., 
2006). Briefly, cells were exposed to 1 µg/ml LPS (InvivoGen USA) and 25 
ng/ml interferon gamma (eBioscience USA) for 24 hrs for M1 stimulation. Cells 
were cultured with 25 ng/ml IL-4 (eBioscience USA) for M2 stimulation. Human 
macrophages were generated using a previously published protocol (Beyer et 
al., 2012). Briefly, peripheral blood monocytes were collected from two healthy 
male volunteers, cells were then plated on 15cm dishes in DMEM 
supplemented with 10% FBS, L-Glutamine, penicillin/streptomycin, and 
100ng/ml human M-CSF (eBiosciences USA) for seven days. After culture, cells 
were lifted from 15cm plates as described for BMM’s and plated in 24 well 
plates for 48hrs. Macrophages were then left untreated (control) or 
supplemented with 1 µg/ml LPS and 25ng/ml human interferon gamma 
(eBiosciences USA), or human IL-4 25ng/ml (eBiosciences USA) for 24hrs to 
generate M1 or M2 macropahges respectively.  For MMR blocking 5 mg/ml 
mannan from Saccharomyces cerevisiae (Invitrogen) was added to cells for 5 
min prior to the addition of particles. 
 
Particle Uptake. For confocal microscopy particle uptake experiments, stock 
media was made with 75 µg/ml of 300 nm PRINT particles. Media on the cells 
was then exchanged for media + FBS + particles. Cells were returned to the 
incubator for 20 min. Media with particles was removed and cells were washed 
3X with warm PBS + 5% FBS to remove particles, then 2X with PBS-serum. 
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Cells were then fixed with ice cold 4% paraformaldehyde in Krebs buffer. Cells 
were permeabilized with 0.1% Triton in PBS for 5 min. F-actin was stained with 
Alexa 488 phalloidin (Invitrogen). Coverslips were mounted on glass slides. For 
flow cytometry, cells were exposed to particles and washed as described for 
microscopy. After washing cells were placed in ice cold PBS supplemented with 
5% FBS and 0.5mM ETDA on ice for 10min followed by gentle scraping to 
remove from plastic. 
 
Fixed Cell Imaging and analysis. Cells were imaged using an Olympus 
FV1000 laser scanning confocal microscope. Using a 10X objective, Z stacks 
were taken in 3 random fields of the coverslip in the Alexa 488 channel to 
image the cell body and Alexa 633 to image the particles. Each Z stack was 
then exported to ImageJ and turned into 2 maximum intensity projections of the 
cell body (phalloidin) and the particles. Single cells were then outlined by 
automated thresholding in the phalloidin channel and particle fluorescence 
intensity was acquired in the 633 nm channel. A total of 50 random cells were 
analyzed per coverslip. The results from cells from four mice were then 
averaged to determine the relative particle uptake. 
 
Flow cytometry of cultured macrophages. Cells were analyzed using a Dako 
cyan ADP flow cytometer (Beckman Coulter). Live single cells were selected 
using forward scatter and side scatter. Particle fluorescence was detected in the 
far red channel with a 633nm laser. The average fluorescence intensity of live 
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single cells was calculated and reported. All analysis was performed using 
FlowJo software. 
 
Statistics. All statistical analysis was performed using GraphPad Prism 5. P 
values less than .05 were considered significant. For t test unpaired two tailed t 
test was used, for ANOVA tests 1 way ANOVA with Dunnett’s post-test was 
used. All error bars represent ± SEM. 
 
Study approval. Studies with human samples were performed under IRB #12-
1858 with approval from the Office of Human Research Ethics at the University 
of North Carolina Chapel Hill. All animal experiments were performed with 
approval of the University of North Carolina Institutional Animal Care and Use 
Committee. 
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